Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study described the clinical and genetic features of two Iranian siblings with hereditary vitamin D resistant rickets, identifying a specific VDR gene mutation contributing to their symptoms.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This review discusses the effects of low-level laser therapy in various biological processes for wound healing and tissue repair and reports no new results.

This study suggests that CSLD1 is key to nitrogen-dependent root hair elongation and regulation of AMT1;2 expression in rice roots.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This article introduces a series on low level laser light therapy, focusing on its science, regulatory aspects, and controlled trial methodologies, but reports no new clinical results.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

In this study, the authors reported that AtRXR3, a phosphorus-inducible DUF506 protein, modulates root hair growth under phosphorus stress by interacting with calmodulin and influencing calcium oscillations.

The researchers reported that disrupting ATRA signaling by deleting RDHE genes in the hair follicle led to altered hair follicle cycles, composition, and gene expression, indicating RDHEs' role in hair follicle signaling coordination.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

In this study, a child's diagnosis of Silver-Russell syndrome was confirmed through phenotype data, genetic testing, and the exclusion of other developmental conditions, revealing a need for a multidisciplinary care approach.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study highlights a rare case of vitamin D-dependent rickets type 2A caused by a heterozygous mutation in the vitamin D receptor gene, emphasizing the complexity of managing this condition with high-dose calcium and vitamin D therapy.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

In this study, a Chinese Han family with hereditary vitamin D-resistant rickets was found to have a homozygous missense mutation in the VDR gene, and the affected individual uniquely responded well to treatment with oral calcium and low-dose calcitriol.

In this case report, researchers observed that local radiation therapy to the orbits may not be sufficient to halt progression of new retinal lesions in older patients, even when the disease initially appears confined to the intraocular space.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This article compares two rare genetic diseases, vitamin D-dependent rickets type 1 and type 2, focusing on their similar presentations of hypocalcemia and rickets in infancy, but reports no new clinical results.

This review found that laser-assisted drug delivery in humans was associated with several adverse effects, but no life-threatening events were reported in the studies examined.

This review discusses the differential diagnosis of low-renin hypertension and highlights recent genetic discoveries related to familial forms, but it presents no new clinical results.

LRIG1 protein affects hair growth by regulating skin receptors, leading to hair loss when overexpressed.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

A genetic mutation caused severe rickets and alopecia in an Indian patient, but high-dose calcium and phosphate treatment improved their condition.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This article discusses the applications and proposed benefits of LED low level light therapy for various conditions like acne, wound healing, and pain relief, but provides no new clinical results.

In this case study, DDS treatment for LABD was complicated by hemolytic anemia and alopecia, suggesting the need for careful monitoring of these potential side effects.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

In this study, a novel VDR gene mutation was identified in a child with HVDRR, and the researchers observed that high-dose intravenous calcium therapy led to significant and sustained improvement in rickets symptoms.

This review compiles current research on the role of long non-coding RNAs in regulating muscle growth and regeneration processes, particularly their influence on Duchenne muscular dystrophy, and reports no new clinical results.